Table 2.

Demographics: pwMS and pwNIc who received tixagevimab/cilgavimab by location

pwMS and pwNIc received tixagevimab/cilgavimab by location			Total n=167
	Hospital infusion centre n=54	Hospital vaccination hub n=66	Local supercare pharmacy n=47
Age (years)
Mean	51.35	49.80	51.36
SD	13.25	12.06	11.18
Sex, n (%)
Female	(74.1%)	(71.2%)	(78.7%)
EDSS
Mean	3.42	3.27	2.63
SD	2.48	2.48	2.16
COVID-19 n (%) vaccine doses no 3=>	(90.7%)	(95.5%)	(94.0%)
DMT treatment n (%)
Ocrelizumab	45 (83.33%)	44 (66.67%)	34 (72.34%)
Ofatumumab	0	5 (7.58%)	2 (4.26%)
Rituximab	7 (12.96%)	2 (3.03%)	0
Fingolimod	0	7 (10.61%)	10 (21.28%)
Siponimod	0	5 (7.58%)	1 (2.13%)
Other	2 (3.70%)	3 (4.55%)	0

DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale Score; pwMS, people with multiple sclerosis; pwNIc, people with neuroimmunological conditions.